205 related articles for article (PubMed ID: 31492560)
21. Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2.
Karakashev SV; Reginato MJ
Oncotarget; 2015 Feb; 6(4):1967-80. PubMed ID: 25596742
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules.
Yu Y; Gaillard S; Phillip JM; Huang TC; Pinto SM; Tessarollo NG; Zhang Z; Pandey A; Wirtz D; Ayhan A; Davidson B; Wang TL; Shih IeM
Cancer Cell; 2015 Jul; 28(1):82-96. PubMed ID: 26096845
[TBL] [Abstract][Full Text] [Related]
23. EGFR-Specific Tyrosine Kinase Inhibitor Modifies NK Cell-Mediated Antitumoral Activity against Ovarian Cancer Cells.
Mallmann-Gottschalk N; Sax Y; Kimmig R; Lang S; Brandau S
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31546690
[TBL] [Abstract][Full Text] [Related]
24. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
Huang Y; Li X; Jiang J; Frank SJ
Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991
[TBL] [Abstract][Full Text] [Related]
25. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
[TBL] [Abstract][Full Text] [Related]
26. Proteomic analysis of temporally stimulated ovarian cancer cells for biomarker discovery.
Marzinke MA; Choi CH; Chen L; Shih IeM; Chan DW; Zhang H
Mol Cell Proteomics; 2013 Feb; 12(2):356-68. PubMed ID: 23172893
[TBL] [Abstract][Full Text] [Related]
27. Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities.
Hung WY; Chang JH; Cheng Y; Chen CK; Chen JQ; Hua KT; Cheng CW; Hsiao M; Chung CL; Lee WJ; Chien MH
Cell Physiol Biochem; 2018; 51(1):337-355. PubMed ID: 30453282
[TBL] [Abstract][Full Text] [Related]
28. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
29. Exon 4 deletion variant of epidermal growth factor receptor enhances invasiveness and cisplatin resistance in epithelial ovarian cancer.
Zhang P; Zhang P; Zhou M; Jiang H; Zhang H; Shi B; Pan X; Gao H; Sun H; Li Z
Carcinogenesis; 2013 Nov; 34(11):2639-46. PubMed ID: 23764753
[TBL] [Abstract][Full Text] [Related]
30. Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns.
Wosikowski K; Schuurhuis D; Johnson K; Paull KD; Myers TG; Weinstein JN; Bates SE
J Natl Cancer Inst; 1997 Oct; 89(20):1505-15. PubMed ID: 9337347
[TBL] [Abstract][Full Text] [Related]
31. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
[TBL] [Abstract][Full Text] [Related]
32. ErbB Receptors and Cancer.
Wang Z
Methods Mol Biol; 2017; 1652():3-35. PubMed ID: 28791631
[TBL] [Abstract][Full Text] [Related]
33. Biased signaling downstream of epidermal growth factor receptor regulates proliferative versus apoptotic response to ligand.
Ali R; Brown W; Purdy SC; Davisson VJ; Wendt MK
Cell Death Dis; 2018 Sep; 9(10):976. PubMed ID: 30250119
[TBL] [Abstract][Full Text] [Related]
34. Dual down-regulation of EGFR and ErbB2 by berberine contributes to suppression of migration and invasion of human ovarian cancer cells.
Chuang TC; Wu K; Lin YY; Kuo HP; Kao MC; Wang V; Hsu SC; Lee SL
Environ Toxicol; 2021 May; 36(5):737-747. PubMed ID: 33325633
[TBL] [Abstract][Full Text] [Related]
35. [Clinical significance of targeting drug-based molecular biomarkers expression in ovarian clear cell carcinoma].
Li MJ; Li HR; Cheng X; Bi R; Tu XY; Liu F; Chen LH
Zhonghua Fu Chan Ke Za Zhi; 2017 Dec; 52(12):835-843. PubMed ID: 29325268
[No Abstract] [Full Text] [Related]
36. Subcellular distribution of a fluorescence-labeled combi-molecule designed to block epidermal growth factor receptor tyrosine kinase and damage DNA with a green fluorescent species.
Todorova MI; Larroque AL; Dauphin-Pierre S; Fang YQ; Jean-Claude BJ
Mol Cancer Ther; 2010 Apr; 9(4):869-82. PubMed ID: 20354119
[TBL] [Abstract][Full Text] [Related]
37. p85β alters response to EGFR inhibitor in ovarian cancer through p38 MAPK-mediated regulation of DNA repair.
Mak VC; Li X; Rao L; Zhou Y; Tsao SW; Cheung LW
Neoplasia; 2021 Jul; 23(7):718-730. PubMed ID: 34144267
[TBL] [Abstract][Full Text] [Related]
38. Blocking epidermal growth factor receptor activation by 3,3'-diindolylmethane suppresses ovarian tumor growth in vitro and in vivo.
Kandala PK; Wright SE; Srivastava SK
J Pharmacol Exp Ther; 2012 Apr; 341(1):24-32. PubMed ID: 22205686
[TBL] [Abstract][Full Text] [Related]
39. The chemokine CXCL1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor.
Bolitho C; Hahn MA; Baxter RC; Marsh DJ
Endocr Relat Cancer; 2010 Dec; 17(4):929-40. PubMed ID: 20702723
[TBL] [Abstract][Full Text] [Related]
40. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]